Health Catalyst (HCAT) to Release Quarterly Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.08 by $0.04. The business had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.21) EPS. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Health Catalyst Trading Down 0.3 %

Shares of NASDAQ:HCAT opened at $7.68 on Tuesday. The company has a market capitalization of $464.41 million, a price-to-earnings ratio of -5.12 and a beta of 1.32. Health Catalyst has a 12-month low of $5.42 and a 12-month high of $11.41. The business has a 50-day moving average price of $7.96 and a 200 day moving average price of $7.08.

Wall Street Analysts Forecast Growth

HCAT has been the subject of a number of recent analyst reports. Piper Sandler dropped their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Evercore ISI lifted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Stephens decreased their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. JPMorgan Chase & Co. lifted their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and an average target price of $11.90.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the sale, the chief operating officer now owns 134,899 shares of the company’s stock, valued at $1,036,024.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the transaction, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at approximately $1,036,024.32. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,187 shares of company stock valued at $226,171 in the last three months. 2.50% of the stock is owned by corporate insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.